List of Excipients in Branded Drug VALACYCLOVIR

Generic Drugs Containing VALACYCLOVIR

Company	Ingredient	NDC	Excipient
Camber Pharmaceuticals Inc	valacyclovir	31722-704	CELLULOSE, MICROCRYSTALLINE
Camber Pharmaceuticals Inc	valacyclovir	31722-704	CROSPOVIDONE
Camber Pharmaceuticals Inc	valacyclovir	31722-704	FD&C BLUE NO. 2

What are the Most Frequently-Used Excipients in VALACYCLOVIR?

# Of NDCs	Excipient
18	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
36	CELLULOSE, MICROCRYSTALLINE
2	CI 77891

Valacyclovir Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Valacyclovir is a mature, genericized oral antiviral with limited active-ingredient differentiation. Commercial value is concentrated in formulation execution: smaller tablets, rapid disintegration, moisture control, pediatric usability, packaging stability, and lower manufacturing cost. The strongest opportunities are differentiated oral dosage forms and platform products that improve administration without changing the established pharmacokinetic profile.

What is the FDA regulatory status of valacyclovir?

Valacyclovir hydrochloride is the oral prodrug of acyclovir. FDA-approved products are indicated for herpes zoster, genital herpes, herpes labialis, and selected pediatric herpesvirus infections. The reference product, Valtrex, was developed by GlaxoSmithKline and approved under NDA 020487. Generic valacyclovir hydrochloride tablets are approved through the ANDA pathway.

Attribute	Current position
Active ingredient	Valacyclovir hydrochloride
Pharmacologic class	Nucleoside analogue antiviral
Reference product	Valtrex
Original sponsor	GlaxoSmithKline
Primary dosage form	Immediate-release film-coated tablet
Common strengths	500 mg and 1 g
FDA pathway for generics	ANDA
Current market structure	Multiple generic manufacturers plus limited branded supply
Primary commercial barrier	Cost, scale, supply reliability, bioequivalence, and payer contracting
Main formulation opportunity	Patient-friendly oral products with equivalent systemic exposure

Valacyclovir is rapidly converted to acyclovir after oral administration. The conversion improves oral exposure compared with oral acyclovir, making the established immediate-release tablet clinically effective across several dosing regimens (U.S. Food and Drug Administration [FDA], 2024a).

What excipients are used in valacyclovir tablets?

Valacyclovir tablets generally use conventional immediate-release excipients. Public labeling for reference and generic products identifies excipient classes such as microcrystalline cellulose, crospovidone or other disintegrants, povidone, colloidal silicon dioxide, magnesium stearate, and film-coating materials including hypromellose, polyethylene glycol, titanium dioxide, and related coating components. Exact compositions differ by manufacturer and strength (FDA, 2024a; DailyMed, 2024).

Excipient function	Common candidate excipients	Relevance to valacyclovir
Diluent and compression aid	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls tablet size, hardness, and manufacturability
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup and consistent dissolution
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet strength
Glidant	Colloidal silicon dioxide	Improves powder flow and blend uniformity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Film former	Hypromellose, polyvinyl alcohol	Protects the tablet and improves swallowability
Plasticizer	Polyethylene glycol, triacetin	Improves coating flexibility
Opacifier or colorant	Titanium dioxide, iron oxides, approved dyes	Provides product identification and light protection where needed

A commercial formulation should not assume that the branded formulation is the optimal generic composition. A development team can obtain equivalent dissolution and bioequivalence using a different excipient architecture, provided the formulation remains manufacturable and stable.

How should an excipient strategy address valacyclovir’s technical risks?

The formulation strategy should prioritize process robustness over novelty. Valacyclovir products are administered at relatively high milligram strengths, particularly the 1 g tablet. Tablet mass, mechanical strength, disintegration, powder flow, and moisture management therefore influence commercial performance.

Tablet size and swallowability

The 1 g strength creates a direct tablet-size constraint. A high-density filler can reduce tablet volume, while a low-density filler may improve compression but increase tablet size. The optimal selection depends on:

• Drug load and bulk density
• Direct compression versus granulation
• Target tablet hardness
• Disintegration time
• Coating weight
• Packaging requirements

A bilayer or multilayer tablet is unlikely to be necessary for the standard immediate-release product and would add manufacturing complexity. A conventional high-load tablet with optimized filler-disintegrant balance is more commercially defensible.

Disintegration and dissolution

Valacyclovir products should maintain rapid and reproducible dissolution across relevant pH conditions. Excessive lubricant, over-granulation, high compression force, or excessive binder can slow disintegration and dissolution. Crospovidone and croscarmellose sodium are practical candidates for screening because they provide rapid water uptake without requiring a modified-release design.

The development target should be an immediate-release dissolution profile that matches the reference product closely enough to reduce bioequivalence risk. A formulation that dissolves substantially faster is not automatically superior if it changes exposure or creates batch-to-batch variability.

Moisture control

Moisture can affect powder flow, tablet strength, chemical stability, and coating performance. The formulation program should evaluate:

• Water activity and equilibrium moisture
• Hygroscopicity of the active ingredient and excipients
• Granulation water exposure
• Residual moisture after processing
• Stability under accelerated and long-term conditions
• Blister versus bottle packaging

A low-moisture direct-compression process can reduce process steps. Wet granulation may improve content uniformity and compression but creates a larger moisture-control burden. Packaging with a high moisture barrier may be more valuable than adding a complex excipient system.

Lubrication and blend uniformity

Magnesium stearate is widely used but can impair dissolution when overmixed or used at excessive levels. Lubricant concentration and blending time should be treated as critical process parameters. Sodium stearyl fumarate may be evaluated where magnesium stearate produces unacceptable dissolution or compression behavior, although the substitution requires its own stability, process, and regulatory assessment.

Excipient safety and regulatory acceptability

An ANDA formulation should use excipients with established precedent in oral solid dosage forms and suitable FDA Inactive Ingredient Database support for the proposed route, dosage form, and level. Novel excipients increase toxicology, regulatory, and supply-chain risk. The commercial justification for a novel excipient is weak unless it enables a meaningful dosage-form advantage, such as a pediatric liquid, orally disintegrating tablet, or improved stability profile (FDA, 2019).

What formulations are protected or commercially available for valacyclovir?

The dominant product is the immediate-release film-coated tablet. The reference product and generic products are not limited to one universal excipient composition. Excipient selection is generally manufacturer-specific, while the active ingredient, strength, dosage form, quality attributes, and bioequivalence requirements remain constrained.

Immediate-release tablets

This is the lowest-risk commercial segment. Development advantages include:

• Established clinical dosing
• Mature manufacturing technology
• Straightforward ANDA pathway
• Broad prescriber familiarity
• Multiple API and excipient suppliers

The disadvantage is intense price competition. A new tablet manufacturer generally needs a lower cost of goods, reliable supply, contract-manufacturing capacity, or a differentiated channel strategy.

Orally disintegrating tablets

An orally disintegrating tablet could address patients with swallowing difficulty, acute herpes labialis, or limited access to water. Candidate excipient systems include mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and taste-masking materials.

The main technical problem is dose loading. A 1 g orally disintegrating tablet may become too large for practical administration. A lower-strength ODT could be more feasible but may require multiple units per dose. The product would need robust disintegration, acceptable mouthfeel, mechanical strength, and bioequivalence.

Oral suspension or reconstitutable powder

A liquid dosage form could serve pediatric patients and adults who cannot swallow tablets. The commercial opportunity is constrained by:

• High drug concentration requirements
• Palatability
• Chemical and microbiological stability
• Sedimentation or caking
• Preservative compatibility
• Reconstitution instructions
• Dosing-device accuracy

A suspension could use suspending agents such as xanthan gum, microcrystalline cellulose-carboxymethylcellulose combinations, or hypromellose. Sweeteners and flavors would require careful compatibility and palatability testing. The product should not be positioned as a simple excipient substitution for tablets. It may require a separate regulatory strategy, stability program, and bioequivalence assessment.

Sprinkle or dispersible granules

Granules that can be dispersed in water or soft food may offer a practical alternative to a liquid suspension. This approach can reduce packaging volume and improve dose portability. The main risks are dose recovery, particle segregation, taste, moisture sensitivity, and administration instructions. A sprinkle product is more defensible if it provides a clear advantage over crushing existing tablets.

Modified-release products

Modified-release valacyclovir has limited clinical rationale because the approved product is used for short courses or defined suppressive regimens, and the active moiety is rapidly generated after absorption. A modified-release product would require a strong pharmacokinetic and adherence rationale. It would also create more complex development, bioequivalence, and manufacturing requirements.

How many patents cover valacyclovir and its formulations?

The core valacyclovir product is a mature small-molecule product whose principal market exclusivity has expired. Current commercial barriers are therefore more likely to involve formulation, process, manufacturing, device, trademark, and regulatory exclusivities than broad composition-of-matter protection.

Patent analysis should separate four categories:

Patent category	Commercial relevance
Core active-ingredient patents	Historical protection; generally expired for the original product
Formulation patents	May cover excipient combinations, release profiles, stability, or dosage forms
Method-of-use patents	May cover dosing schedules or specific patient populations
Manufacturing patents	May affect API purification, crystalline form, yield, or impurity control

A formulation patent has value only if it covers a commercially necessary product attribute and can withstand validity and infringement challenges. Broad claims to conventional excipients such as microcrystalline cellulose, povidone, or magnesium stearate are difficult to defend unless tied to a specific ratio, process, dissolution profile, stability result, or dosage-form architecture.

When does valacyclovir lose exclusivity?

Valacyclovir has already lost the principal exclusivities associated with the original Valtrex product. Generic manufacturers have entered the market, and the product is generally treated as a mature generic opportunity rather than a protected innovative medicine.

Exclusivity type	Valacyclovir position
Original composition protection	Historical and no longer the primary commercial barrier
New chemical entity exclusivity	Expired
Reference-product market exclusivity	Expired
Generic entry pathway	Established ANDA pathway
Current competitive issue	Price, supply, quality, and differentiated dosage forms

Specific Orange Book patent listings and expiration dates must be reviewed against the current FDA Orange Book record for the relevant reference product and dosage form. A legacy patent associated with Valtrex does not necessarily block a current generic tablet, and a listing may have no practical effect if the patent has expired or the generic applicant has addressed it through a Paragraph IV certification (FDA, 2024b).

What is the Orange Book and Paragraph IV status of valacyclovir?

The Orange Book identifies approved drug products and, where applicable, patents and exclusivities submitted by reference-product sponsors. Generic applicants must certify against listed patents under section 505(j)(2)(A)(vii) of the Federal Food, Drug, and Cosmetic Act.

For a mature valacyclovir tablet product, the relevant certification possibilities are:

• Paragraph I: no patent information is listed
• Paragraph II: listed patents have expired
• Paragraph III: the applicant will wait until patent expiration
• Paragraph IV: the listed patent is invalid, unenforceable, or will not be infringed

A Paragraph IV filing can trigger patent litigation and a potential 30-month stay, subject to statutory conditions. Because valacyclovir has been genericized for years, the commercial relevance of any remaining listed patent depends on the exact strength, dosage form, patent scope, and litigation history. A formulation entrant should conduct a current, product-specific Orange Book review rather than rely on historical Valtrex patent summaries.

Which companies are challenging or competing with valacyclovir?

The market includes generic manufacturers, contract manufacturers, pharmacy suppliers, and branded-product distributors. Competition is typically based on procurement economics rather than clinical differentiation.

Relevant competitor groups include:

1. Large generic manufacturers with national distribution.
2. Regional manufacturers supplying wholesalers and health systems.
3. Contract development and manufacturing organizations offering tablet production.
4. Specialty or private-label companies targeting cash-pay, telehealth, and mail-order channels.
5. Developers of alternative dosage forms.

The most defensible commercial position is usually a differentiated product with a clear channel advantage. A conventional 500 mg or 1 g tablet without a cost or supply advantage faces rapid price compression.

What licensing deals and manufacturing opportunities exist?

Valacyclovir is suitable for licensing and contract-manufacturing arrangements because the active ingredient and tablet process are mature. Potential deal structures include:

Opportunity	Likely partner	Value proposition
API supply agreement	Qualified API manufacturer	Lower cost and dual sourcing
ANDA asset licensing	Generic pharmaceutical company	Faster market entry
Private-label supply	Telehealth or pharmacy platform	Branded distribution without internal manufacturing
Pediatric liquid development	Specialty generic company	Patient-access differentiation
ODT or dispersible product	Drug-delivery developer	Administration advantage
Regional commercialization	Local distributor	Geographic market access
Dual-source manufacturing	CMO and finished-dose sponsor	Supply resilience

Manufacturing IP may matter more than formulation patents. Critical barriers can include API impurity control, particle-size consistency, compression performance, coating throughput, cleaning validation, and stability packaging. A supplier with reliable valacyclovir API and validated tablet capacity can have greater commercial leverage than a company holding a narrow excipient patent.

What geographic markets offer valacyclovir opportunities?

The strongest opportunities are in markets with established antiviral diagnosis, generic reimbursement, and high pharmacy distribution. Regulatory strategy differs by jurisdiction.

Region	Primary regulatory and commercial issue
United States	ANDA approval, FDA labeling, Orange Book review, payer pricing
European Union	Decentralized or national generic authorization, local reimbursement
United Kingdom	MHRA authorization and National Health Service procurement
Canada	Health Canada generic submission and provincial reimbursement
Latin America	National registration, local bioequivalence, distributor access
Asia-Pacific	Country-specific registration, local manufacturing, price controls

A formulation developed for the United States may require different excipient justifications, labeling, stability data, or bioequivalence evidence elsewhere. Titanium dioxide restrictions, colorant rules, preservative requirements, and pediatric excipient policies can affect international commercialization.

What revenue exposure and launch scenarios apply to valacyclovir?

Valacyclovir revenue is volume-driven. The market is exposed to generic price erosion, wholesaler consolidation, reimbursement pressure, and episodic supply shortages. Revenue potential depends on product positioning rather than the underlying clinical novelty of the active ingredient.

Launch scenario	Product profile	Commercial outlook
Lowest-cost tablet	Standard 500 mg and 1 g tablets	High volume, low margin
Supply-reliable generic	Standard tablets with dual sourcing	Moderate margin and institutional value
Patient-friendly product	ODT, dispersible, or liquid	Lower volume, higher potential margin
Premium packaging	Moisture-protective blister or unit dose	Useful for adherence and stability channels
Specialty pediatric product	Taste-masked liquid or granules	Differentiated but development-intensive
Modified-release product	Extended exposure or reduced dosing frequency	High regulatory and clinical risk

A launch based solely on a new excipient combination is weak. The excipient strategy must create a measurable advantage in dissolution, stability, dose administration, manufacturing yield, or patient adherence.

How strong is the valacyclovir patent estate?

The legacy patent estate is commercially weak relative to active innovative-drug portfolios because the original product has long been genericized. New formulation claims can still create protection, but the claims must be narrow enough to be patentable and broad enough to cover a commercially meaningful product.

A strong formulation patent would ideally include:

• A defined valacyclovir loading range
• Specific excipient classes or ratios
• A measurable dissolution or disintegration profile
• Stability performance under defined conditions
• A manufacturing process linked to the product attributes
• Claims that cover commercial strengths and packaging configurations

A weak patent would claim a conventional tablet containing valacyclovir and routine excipients without unexpected performance or a technically meaningful relationship between composition and result.

What generic launch risks exist?

The principal generic launch risks are:

• Bioequivalence failure caused by dissolution or formulation differences
• Tablet size that reduces patient acceptability
• Moisture-driven degradation or packaging failure
• API impurity variability
• Inadequate content uniformity at high drug loading
• Coating defects and inconsistent appearance
• Excessive lubricant exposure
• Inadequate pediatric palatability
• Supply interruption from a single API source
• Price erosion after multiple generic approvals

A staged development plan should begin with the standard immediate-release tablet, then assess whether a differentiated dosage form creates enough commercial value to justify additional regulatory and manufacturing investment.

Key Takeaways

• Valacyclovir is a mature generic antiviral with expired primary market exclusivity.
• Conventional immediate-release tablets remain the lowest-risk commercial product.
• Excipient selection should focus on compression, disintegration, moisture control, dissolution, and tablet size.
• Microcrystalline cellulose, crospovidone, croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, and hypromellose are practical formulation platforms with established oral-dose precedent.
• The strongest differentiated opportunities are orally disintegrating, dispersible, pediatric liquid, and high-stability unit-dose products.
• Formulation patents must claim specific technical performance, not routine excipient combinations.
• Commercial success is more likely to come from manufacturing reliability, supply security, and patient usability than from broad active-ingredient patent protection.
• A current Orange Book, ANDA, litigation, and regional regulatory review is essential for any product-specific launch decision.

FAQs

Can valacyclovir be formulated as an orally disintegrating tablet?

Yes. The main constraint is dose loading, especially for the 1 g strength. A lower-strength ODT may require multiple units per dose, while a high-load ODT may have unacceptable tablet size or mouthfeel.

Which excipient is best for rapid valacyclovir tablet disintegration?

No single excipient is universally optimal. Crospovidone and croscarmellose sodium are strong screening candidates, but performance depends on drug load, compression force, lubricant level, particle size, and manufacturing process.

Is a valacyclovir oral suspension commercially attractive?

It can be attractive for pediatric and dysphagic populations, but the product faces substantial palatability, stability, preservative, sedimentation, and dosing-device requirements. Its value is greatest where an approved or reliably supplied liquid alternative is limited.

Does a new valacyclovir excipient combination create patent protection?

Not automatically. Patentability generally requires a novel composition or process and a non-obvious technical result, such as improved stability, dissolution, manufacturability, or patient administration.

Is valacyclovir suitable for a 505(b)(2) product?

A novel dosage form may qualify for a 505(b)(2) strategy depending on the product design, regulatory reliance, and extent of new clinical or bridging data. A conventional generic tablet is ordinarily pursued through the ANDA pathway.

References

DailyMed. (2024). Valacyclovir hydrochloride tablet prescribing information. National Library of Medicine.

U.S. Food and Drug Administration. (2019). Guidance for industry: Nonclinical studies for the safety evaluation of pharmaceutical excipients. FDA.

U.S. Food and Drug Administration. (2024a). Valtrex and valacyclovir hydrochloride prescribing information. FDA.

U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. FDA.